Clinical trials: Diabetic Cardiomyopathy
Type 2 Diabetes Mellitus, Cardiovascular Diseases
Soluble TREM-1 in Diabetes-Associated Cardiovascular Complications
Cardiovascular disease is the leading cause of illness and death among individuals with type 2 diabetes mellitus (T2DM). Chronic low-grade inflammation contributes significantly to blood vessel damage, atherosclerosis, and…
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Diseases, Coronary Artery Disease, Heart Failure
- Trial name
- NCT07847112
- Volunteers
- 85 people
- Sponsor
- Assiut University
Left Ventricular Function Systolic Dysfunction, Left Ventricular Function Diastolic Dysfunction
Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI)
The purpose of this study is to investigate the efficacy and mechanism of bone marrow mononuclear cells (BMMNC) transplantation for diabetic and non-diabetic patients with ST-segment elevation myocardial infarction (STEMI)who…
- Conditions
- Left Ventricular Function Systolic Dysfunction, Left Ventricular Function Diastolic Dysfunction, Death, Myocardial Reperfusion Injury
- Trial name
- NCT01307371
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Xijing Hospital
Cardiomyopathy, Diabetic
CARdiomyopathy in Type 2 DIAbetes Mellitus
The objective of the CARDIATEAM clinical study is to assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy using unsupervised clustering approaches based on deep phenotyping (clinical…
- Trial name
- CARDIATEAM (NCT04303364)
- Where
- 17 sites in France, Germany and 3 more
- Volunteers
- 1,256 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies
Tailored Exercise Training Study Among Adults With HFpEF
Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF.
- Trial name
- TEXPEF (NCT07223242)
- Testing
- Moderate-intensity continuous training (MCT), Resistance training, Weight loss
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Texas Southwestern Medical Center
Cardiomyopathy, Diabetic
Impact of Pharmacist in Cardiology Service
The coverage of the diabetes is a multidisciplinary care, with practitioners' implication(hospital and liberal), and other medical and paramedical profession: doctor, pharmacist, male nurse, nutritionist, etc.
- Trial name
- NCT03206294
- Testing
- pharmacist assessment
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Diabetic Cardiomyopathies
Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy
The heart has the ability to respond to different patho-physiological conditions by adapting its energy metabolism. In diabetic subjects, the myocardium uses only fatty acids as a substrate.
- Trial name
- CARDIALA (NCT04141475)
- Testing
- Physiomance acide lipoïque gold
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Type 2 Diabetes, Diabetic Cardiomyopathies
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
- Conditions
- Type 2 Diabetes, Diabetic Cardiomyopathies, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT04826159
- Testing
- IMB-1018972
- Where
- United Kingdom
- Volunteers
- 49 people
- Sponsor
- Imbria Pharmaceuticals, Inc.
Type II Diabetes Mellitus, Diabetes Complications
Lipid Biomarkers for Diabetic Heart Disease
This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function.
- Trial name
- NCT01752842
- Testing
- Fenofibrate
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Washington University School of Medicine
Diabetic Cardiomyopathies
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diabetic Cardiomyopathy at high risk of progression to overt heart failure.
- Trial name
- NCT04083339
- Testing
- AT-001
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 675 people
- Sponsor
- Applied Therapeutics, Inc.
Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2
Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial
Type 2 diabetes mellitus (T2DM) is a well-recognized independent risk factor for heart failure (HF). Whereas the prevalence of HF in the general population is 1-4%, it reaches approximately 12% in T2DM patients.
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2, Cardiomyopathies
- Trial name
- NCT04304560
- Testing
- Dapagliflozin 10 MG
- Volunteers
- 60 people
- Sponsor
- Damanhour University
Diabetes Mellitus, Type II
Detection of Diffuse Scar in Patients With Diabetes
People with diabetes are at an increased risk of heart attacks and heart failure, and it is important to be able to treat people with diabetes who are at risk for heart disease to prevent these outcomes.
- Trial name
- NCT01794091
- Testing
- Eplerenone
- Where
- United States
- Sponsor
- Brigham and Women's Hospital
Heart Failure, Diabetic Cardiomyopathies
The DAPA-MEMRI Trial
Diabetes mellitus is among the top 10 causes of death worldwide with an increasing incidence. Patients with diabetes are at risk of developing heart failure which is characterised by significant changes in the heart muscle…
- Trial name
- DAPA-MEMRI (NCT04591639)
- Testing
- Dapagliflozin 10 milligrams [Farxiga]
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies
CMR in T2DM: The NSR Cohort
This study aims to investigate the myocardial phenotype of patients with type 2 diabetes. From 2016-2019 the investigators recruited a cohort of 296 subjects with type 2 diabetes.
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies, Cardiovascular Magnetic Resonance Imaging, Coronary Microvascular Dysfunction
- Trial name
- NCT05915260
- Testing
- All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion
- Where
- Denmark
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Slagelse Hospital
T2DM (Type 2 Diabetes Mellitus)
Nutritional Therapy for Diabetic Cardiomyopathy
The goal of this study is to determine if nutritional therapy can effectively treat/prevent T2DM and its consequent cardiomyopathy.
- Trial name
- NCT01373814
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington University School of Medicine
Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies
Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus
Background: Heart failure is a major cause of morbidity and mortality in diabetes mellitus, but its pathophysiology is poorly understood.
- Trial name
- PREDICT (NCT03132129)
- Testing
- Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy, Transthoracic echocardiography, Computed tomography coronary artery calcium scoring
- Where
- United Kingdom
- Volunteers
- 593 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Type 2 Diabetes, Diabetic Cardiomyopathy
NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a…
- Conditions
- Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
- Trial name
- STRONG-DM (NCT06593327)
- Testing
- Intensive Prevention Strategy
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetic Cardiomyopathies, Type2 Diabetes
Effect of High-intensity Interval Training on Cardiac Function and Regulation of Glycemic Control in Diabetic Cardiomyopathy
According to data of the International Diabetes Federation (IDF), diabetes in general affects approximately 415 million people worldwide and this number is still increasing.
- Trial name
- NCT03299790
- Testing
- high-intensity interval exercise training (HIIT), moderate-intensity exercise training (MIT)
- Where
- Belgium
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Hasselt University
Diabetic Cardiomyopathies
Diabetic Cardiomyopathy
Diabetes represents one of the 10 leading causes of death in the world and concerns 5% of the French population (> 3.3 million patients). About 30% of diabetic patients will develop heart failure.
- Trial name
- CarDiab (NCT04593173)
- Where
- France
- Volunteers
- 77 people
- Sponsor
- University Hospital, Strasbourg, France
Type2 Diabetes, Heart Failure With Reduced Ejection Fraction
The Effects of SGLTi on Diabetic Cardiomyopathy
Diabetic cardiomyopathy is associated with significant morbidity and mortality. It is considered as a cardiac muscle disorder secondary to diabetes mellitus (DM).
- Trial name
- SGLTi (NCT04200586)
- Testing
- Dapagliflozin
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong